Prellis is leveraging their unique approach to tissue engineering to support the first use of synthetic human tissue for de novo therapeutic antibody discovery. The company’s platform allows for 3-5x more rapid development of highly specific antibodies with high affinity, generating dozens of diverse candidates for each target, at a cost to the company of an order of magnitude cheaper than prior methods.